AI Article Synopsis
- Progressive multifocal leukoencephalopathy (PML) is a serious risk associated with the use of natalizumab (NAT) for treating relapsing multiple sclerosis (MS).
- JC virus serology is a key risk factor for developing PML, and monitoring this status is critical for patients on NAT.
- If a patient shows seroconversion, careful consideration is required before discontinuing NAT to prevent a rebound of MS symptoms, and JC virus index values can aid in making informed treatment decisions.
Article Abstract
Progressive multifocal leukoencephalopathy (PML) is the most feared complication when natalizumab (NAT) is used in the treatment of relapsing multiple sclerosis (MS). JC virus serologic status is a currently established risk factor for PML. When seroconversion occurs, NAT discontinuation should be based on a solid rationale to avoid an MS inflammatory resurgence. The JC virus index value may also provide further useful information to help practitioners and patients in their decision process.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.msard.2015.04.005 | DOI Listing |
Publication Analysis
Top Keywords
natalizumab effective
4
effective controlling
4
controlling inflammatory
4
inflammatory rebound
4
rebound discontinuation
4
discontinuation failure
4
failure alternative
4
alternative treatment
4
treatment progressive
4
progressive multifocal
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!